226 related articles for article (PubMed ID: 33514790)
1. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
Singh SK; Kumar D; Malani H; Rathore AS
Sci Rep; 2021 Jan; 11(1):2487. PubMed ID: 33514790
[TBL] [Abstract][Full Text] [Related]
2. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
[TBL] [Abstract][Full Text] [Related]
3. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
Brown KA; Rajendran S; Dowd J; Wilson DJ
Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
[TBL] [Abstract][Full Text] [Related]
4. Biophysical study of bevacizumab structure and bioactivity under thermal and pH-stresses.
Sousa F; Sarmento B; Neves-Petersen MT
Eur J Pharm Sci; 2017 Jul; 105():127-136. PubMed ID: 28502677
[TBL] [Abstract][Full Text] [Related]
5. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
[TBL] [Abstract][Full Text] [Related]
6. In-depth size and charge variants characterization of monoclonal antibody with native mass spectrometry.
Dai J; Ji C
Anal Chim Acta; 2023 Jul; 1265():341360. PubMed ID: 37230578
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of charge variants of infliximab biosimilar HS626.
Yuan JJ; Gao D; Hu F; Shi Y; Wu ZH; Hu CQ; Huang XD; Fang WJ; Zhang HT; Wang HB
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122485. PubMed ID: 33360415
[TBL] [Abstract][Full Text] [Related]
8. Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin
Gurel B; Berksoz M; Capkin E; Parlar A; Pala MC; Ozkan A; Capan Y; Daglikoca DE; Yuce M
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015197
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Monitoring of Monoclonal Antibody Variants by Strong Cation-Exchange Chromatography Hyphenated to Mass Spectrometry to Assess Quality Attributes of Rituximab-Based Biotherapeutics.
Di Marco F; Berger T; Esser-Skala W; Rapp E; Regl C; Huber CG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445776
[TBL] [Abstract][Full Text] [Related]
10. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat.
Zhao YY; Wang N; Liu WH; Tao WJ; Liu LL; Shen ZD
PLoS One; 2016; 11(3):e0151874. PubMed ID: 26987122
[TBL] [Abstract][Full Text] [Related]
11. Multiattribute Monitoring of Antibody Charge Variants by Cation-Exchange Chromatography Coupled to Native Mass Spectrometry.
Haberger M; Heidenreich AK; Hook M; Fichtl J; Lang R; Cymer F; Adibzadeh M; Kuhne F; Wegele H; Reusch D; Bonnington L; Bulau P
J Am Soc Mass Spectrom; 2021 Aug; 32(8):2062-2071. PubMed ID: 33687195
[TBL] [Abstract][Full Text] [Related]
12. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
13. A Charge Variant of Bevacizumab Offers Enhanced FcRn-Dependent Pharmacokinetic Half-Life and Efficacy.
Singh SK; Kumar D; Nagpal S; Dubey SK; Rathore AS
Pharm Res; 2022 May; 39(5):851-865. PubMed ID: 35355206
[TBL] [Abstract][Full Text] [Related]
14. Assessment of change in the basic variants composition of trastuzumab during dilution in saline for administration.
Gupta S; Schöneich C; Rathore AS
Eur J Pharm Biopharm; 2024 Jun; 199():114295. PubMed ID: 38636881
[TBL] [Abstract][Full Text] [Related]
15. Characterization of therapeutic proteins by cation exchange chromatography-mass spectrometry and top-down analysis.
Shi RL; Xiao G; Dillon TM; Ricci MS; Bondarenko PV
MAbs; 2020; 12(1):1739825. PubMed ID: 32292112
[TBL] [Abstract][Full Text] [Related]
16. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Nov; 176():112802. PubMed ID: 31446298
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Recombinant Monoclonal Antibody Charge Variants Using OFFGEL Fractionation, Weak Anion Exchange Chromatography, and Mass Spectrometry.
Neill A; Nowak C; Patel R; Ponniah G; Gonzalez N; Miano D; Liu H
Anal Chem; 2015 Jun; 87(12):6204-11. PubMed ID: 25977987
[TBL] [Abstract][Full Text] [Related]
18. Insights into the generation of monoclonal antibody acidic charge variants during Chinese hamster ovary cell cultures.
Tang H; Miao S; Zhang X; Fan L; Liu X; Tan WS; Zhao L
Appl Microbiol Biotechnol; 2018 Feb; 102(3):1203-1214. PubMed ID: 29238873
[TBL] [Abstract][Full Text] [Related]
19. Assessment of structural and functional similarity of biosimilar products: Bevacizumab as a case study.
Bhattacharya S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Sep; 1229():123896. PubMed ID: 37776677
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the correlation between charge and glycosylation of IgG1 variants by liquid chromatography-mass spectrometry.
Yang JM; Ai J; Bao Y; Yuan Z; Qin Y; Xie YW; Tao D; Fu D; Peng Y
Anal Biochem; 2014 Mar; 448():82-91. PubMed ID: 24287081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
